contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


senzagen-secures-orders-of-sek-13-million-from-a-us-based-world-leading-chemical-company

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund. 

SenzaGen

SenzaGen has received new assignments from an existing customer in the chemicals industry with a total order value of approximately SEK 1.3 million. The assignments were secured at the end of...

<div class="mfn-preamble"><p><strong>SenzaGen has received new assignments from an existing customer in the chemicals industry with a total order value of approximately SEK 1.3 million. The assignments were secured at the end of the third quarter and will be carried out at SenzaGen’s GLP-certified laboratories in Lund and Milan, as well as through a partner laboratory. The testing includes the company’s proprietary non-animal method GARD®skin for skin sensitization, along with complementary methods for other regulatory toxicology endpoints.</strong></p></div><div class="mfn-body"><p>Substances in the chemicals industry are often both challenging to assess and potentially hazardous. Reliable and accurate test results are therefore crucial to ensure they do not cause harm to humans – an area where SenzaGen has solid experience and broad expertise.</p><p>“We support some of the world’s largest chemicals companies in ensuring the safety of their substances. Customers choose us because our advanced test methods make it possible to evaluate even the most challenging chemicals. This order confirms that the SenzaGen Group has a unique and competitive offering that meets the high demands of our customers”, says Peter Nählstedt, President and CEO of SenzaGen.</p><p>The GARD® technology is based on genomics and machine learning and generates highly reliable and accurate decision support for both pure chemicals and more complex substances and mixtures that have traditionally been difficult to test. The test is approved for regulatory use by the OECD in accordance with TG 497 and TG 442E.</p></div><div class="mfn-footer mfn-contacts mfn-ba9271758839"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p><strong>Peter Nählstedt, </strong>President and CEO, SenzaGen AB<br>Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00<br><br><strong>Tina Dackemark Lawesson</strong>, VP Marketing &amp; Communications<br>Email:&nbsp;<a rel="noopener" href="mailto:tina.lawesson@senzagen.com">tina.lawesson@senzagen.com</a>&nbsp;| Tel: +46 46-275 62 00</p></div><div class="mfn-footer mfn-about mfn-59f0b3757870"><p><strong class="mfn-heading-1">About us</strong></p><hr><p>SenzaGen is a corporate group on its way to becoming a leading player in non-animal testing, driving the shift from animal experiments to methods that more accurately reflect human biology. Leveraging cutting-edge technology, the company offers high-performance non-animal test methods and expert advisory services. These methods are more effective, precise, and cost-efficient than traditional animal-based approaches and contribute to a substantial reduction in the number of laboratory animals used worldwide. SenzaGen’s growth strategy focuses on strengthening its position in both established and new markets through direct sales, complementary partnerships, an expanded test portfolio, and recognized thought leadership. The company also maintains a long-term acquisition agenda to accelerate commercial potential. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden, along with subsidiaries in Italy and the USA. For more information, visit <a rel="noopener" href="http://www.senzagen.com">www.senzagen.com</a>.</p><p>SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.&nbsp;</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/17726c55-fd39-4664-bc6f-e377a782b62f/senzagen-secures-orders-of-sek-1-3-million-from-a-us-based-world-leading-chemical-company.pdf" class="mfn-generated mfn-primary">SenzaGen secures orders of SEK 1.3 million from a US-based world-leading chemical company</a></p></div>

SenzaGen secures orders of SEK 1.3 million from a US-based world-leading chemical company